Correction: Assessment of Endoscopic Submucosal Dissection for Treating Duodenal Tumors ≥ 20 mm: A Systematic Review and Meta-Analysis Based on Lesion Size

By
Daisuke Minezaki
Yusaku Takatori
Motohiko Kato
Yasunori Sato
Kohei Takizawa
Koichi Kurahara
Naomi Kakushima
Nobutsugu Abe
Osamu Dohi
Satoru Nonaka
Seiichiro Fukuhara
Shoichi Yoshimizu
Shu Hoteya
Yasushi Yamasaki
Naohisa Yahagi
September 30, 2026

Journal Of Gastroenterology

Original Source(s)

Journal Of Gastroenterology

Correction: Evaluation of endoscopic submucosal dissection as a treatment option for duodenal tumors ≥ 20 mm: a systematic review and meta-analysis by lesion size

by Daisuke Minezaki, Yusaku Takatori, Motohiko Kato, Yasunori Sato, Kohei Takizawa, Koichi Kurahara, Naomi Kakushima, Nobutsugu Abe, Osamu Dohi, Satoru Nonaka, Seiichiro Fukuhara, Shoichi Yoshimizu, Shu Hoteya, Yasushi Yamasaki, Naohisa Yahagi
September 30, 2026

Related Content

European Radiology

5.0 T versus 1.5 T and 3.0 T upper abdominal MRI: a prospective two‑cohort study of image quality and diagnostic confidence

by Liuhong Zhu, Danlan Lian, Funan Wang, Anjie Xie, Jiaqi Wang, Hao Liu, Jianjun Zhou
September 28, 2026

Dana-Farber

Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

September 30, 2026
1 min

Jama Network Open